MX2024003275A - Caix dirigido a proteínas de fusión de il-12 y métodos de uso de las mismas. - Google Patents

Caix dirigido a proteínas de fusión de il-12 y métodos de uso de las mismas.

Info

Publication number
MX2024003275A
MX2024003275A MX2024003275A MX2024003275A MX2024003275A MX 2024003275 A MX2024003275 A MX 2024003275A MX 2024003275 A MX2024003275 A MX 2024003275A MX 2024003275 A MX2024003275 A MX 2024003275A MX 2024003275 A MX2024003275 A MX 2024003275A
Authority
MX
Mexico
Prior art keywords
fusion proteins
methods
polypeptides
polypeptide
caix targeting
Prior art date
Application number
MX2024003275A
Other languages
English (en)
Spanish (es)
Inventor
Pradip Nair
Jaya Bhatnagar
Arvind Vittal Goswami
Harish Kumar Tripurana
Ramakrishnan Melarkode Subbaraman
Shiv Ram Krishn
Srinivas Reddy Boreddy
Reshmi Nair
Avanish K Varshney
Seng - Lai TAN
Original Assignee
Bicara Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bicara Therapeutics Inc filed Critical Bicara Therapeutics Inc
Publication of MX2024003275A publication Critical patent/MX2024003275A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/988—Lyases (4.), e.g. aldolases, heparinase, enolases, fumarase

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
MX2024003275A 2021-09-17 2022-09-16 Caix dirigido a proteínas de fusión de il-12 y métodos de uso de las mismas. MX2024003275A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163245523P 2021-09-17 2021-09-17
PCT/US2022/043762 WO2023043978A2 (en) 2021-09-17 2022-09-16 Caix targeting il-12 fusion proteins and methods of use thereof

Publications (1)

Publication Number Publication Date
MX2024003275A true MX2024003275A (es) 2024-05-07

Family

ID=85603506

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024003275A MX2024003275A (es) 2021-09-17 2022-09-16 Caix dirigido a proteínas de fusión de il-12 y métodos de uso de las mismas.

Country Status (11)

Country Link
US (1) US20240392031A1 (cg-RX-API-DMAC7.html)
EP (1) EP4402158A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024534468A (cg-RX-API-DMAC7.html)
KR (1) KR20240161081A (cg-RX-API-DMAC7.html)
CN (1) CN118369331A (cg-RX-API-DMAC7.html)
AU (1) AU2022345103A1 (cg-RX-API-DMAC7.html)
CA (1) CA3232632A1 (cg-RX-API-DMAC7.html)
IL (1) IL311442A (cg-RX-API-DMAC7.html)
MX (1) MX2024003275A (cg-RX-API-DMAC7.html)
WO (1) WO2023043978A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA202402034B (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200089312A (ko) 2017-11-28 2020-07-24 추가이 세이야쿠 가부시키가이샤 리간드 결합 활성을 조정 가능한 리간드 결합 분자
EP3981428A4 (en) 2019-06-05 2023-07-12 Chugai Seiyaku Kabushiki Kaisha Protease substrate, and polypeptide including protease cleavage sequence
CN115943210A (zh) 2020-01-20 2023-04-07 中外制药株式会社 配体结合融合蛋白
CN120035602A (zh) * 2022-06-17 2025-05-23 辉瑞公司 Il-12变体、抗-pd1抗体、融合蛋白及其用途
EP4739701A2 (en) * 2023-07-07 2026-05-13 Technische Universität München, in Vertretung des Freistaats Bayern Muteins of human interleukin 12
WO2025101133A1 (en) * 2023-11-10 2025-05-15 Agency For Science, Technology And Research Interleukin-12 variants and medical uses thereof
AU2024407051A1 (en) 2023-12-18 2026-07-30 Genzyme Corporation Il-12 loss of potency muteins
WO2025205534A1 (ja) * 2024-03-25 2025-10-02 積水メディカル株式会社 免疫測定方法、精度管理方法、標準試料及び免疫測定試薬

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1418184A1 (en) * 2002-11-08 2004-05-12 Cell Center Cologne GmbH Recombinant fusion protein consisting of the p40 and p35 subunits of IL-12 and a ScFv and use thereof
SI1966238T1 (sl) * 2005-12-30 2012-08-31 Merck Patent Gmbh Variante interlevkina-12P40 z izboljšano stabilnostjo
US20210130430A1 (en) * 2018-05-14 2021-05-06 Werewolf Therapeutics, Inc. Activatable cytokine polypeptides and methods of use thereof
KR102884523B1 (ko) * 2018-10-03 2025-11-10 젠코어 인코포레이티드 IL-12 이종이량체 Fc-융합 단백질
EP4037700A2 (en) * 2019-10-03 2022-08-10 Xencor, Inc. Targeted il-12 heterodimeric fc-fusion proteins
JP7851612B2 (ja) * 2020-04-17 2026-04-27 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 改変il-12及びil-23ポリペプチドとその使用

Also Published As

Publication number Publication date
EP4402158A2 (en) 2024-07-24
ZA202402034B (en) 2025-06-25
EP4402158A4 (en) 2025-07-30
KR20240161081A (ko) 2024-11-12
WO2023043978A3 (en) 2023-09-28
AU2022345103A1 (en) 2024-03-28
WO2023043978A2 (en) 2023-03-23
US20240392031A1 (en) 2024-11-28
JP2024534468A (ja) 2024-09-20
CA3232632A1 (en) 2023-03-23
CN118369331A (zh) 2024-07-19
IL311442A (en) 2024-05-01

Similar Documents

Publication Publication Date Title
CL2022000300A1 (es) Muteínas de interleucina 21 y sus usos para tratar tumores sólidos (divisional de la solicitud no. 202000252)
ZA202402034B (en) Caix targeting il-12 fusion proteins and methods of use thereof
CL2021002241A1 (es) Proteínas de unión condicionalmente activadas restringidas (divisional de la solicitud no. 202000570)
BR112022000371A2 (pt) Anticorpos claudin18 e métodos de tratamento contra câncer
CL2023003607A1 (es) Anticuerpos anti-ccr8 y usos de los mismos
PE20241994A1 (es) Proteina mutante de interleucina-2 y fusion de la misma
MX374810B (es) Anticuerpos 4-1bb anti-humano y usos de los mismos
AR115389A1 (es) Anticuerpo antagonista de cd73
BR112021018608A2 (pt) Anticorpos para claudina-6 e conjugados de fármaco
PE20251254A1 (es) Proteinas de anticuerpo injertadas con citocina y metodos de uso en el tratamiento del cancer
CL2018000358A1 (es) Proteínas de fusión de gitrl y usos de las mismas
CO2024013569A2 (es) Moléculas de unión contra frα
CL2024000459A1 (es) Tubulisinas y conjugados de proteína-tubulisina.
BR112018073221A2 (pt) métodos de previsão da utilidade de proteínas ou seus fragmentos, métodos de seleção e/ou avaliação de modificações de aminoácidos específicas, método de fornecimento de vacinas e vacina
MX2022003306A (es) Inmunocitoquina que comprende un complejo de proteina heterodimerico basado en il-15/il-15ra y su uso.
MX2022015769A (es) Tubulisinas y conjugados de proteina-tubulisina.
CO2023002375A2 (es) Anticuerpos contra ilt2 y uso de los mismos
CO2025017440A2 (es) Anticuerpos de dominio único modificados
MX2021002225A (es) Composiciones y metodos para la reprogramacion de tcr mediante el uso de proteinas de fusion.
AR060104A1 (es) Modulacion de la formacion de huesos
MX2024002407A (es) Anticuerpos y conjugados sirp-alfa.
CO2025007355A2 (es) Anticuerpo anti-trem2 y usos del mismo
CO2022006909A2 (es) Anticuerpos contra el virus de la fiebre amarilla y métodos de su generación y uso
MX2023006869A (es) Proteinas de union condicionalmente biespecificas.
MX2024012582A (es) Composiciones farmaceuticas de proteinas terapeuticas y metodos de uso